OakChart

Pluri Inc

PLURHealthcare·Biotechnology·Israel·Nano·NASD·Nov 11 • 3:59 PM ET

1.20+0.08 (7.14%)
2026-11-12 00:22 CET
Market cap
14.12 USD m
Revenue, TTM
1.02 USD m
Net income, TTM
-23.82 USD m
Free cash flow, TTM
-20.22 USD m
EPS diluted, TTM
-2.45
P/E
-
Compare

Price

PLUR against its 20, 50 and 200-day averages
2050200
1.002.003.004.00245K490KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PLURclose 1.2020-day 1.1150-day 1.11200-day 2.301.2052w low

75.3% under the 52-week high of 4.87 on 13 Nov 2025. 52-week low 0.85 on 7 Oct 2026. Last 15 sessions, 49.0% high to low

Volume 0.85× normal · the line is the 50-bar volume average

Profile

PLUR
52-week range, 9% of the way up
0.854.86

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Employees92
IPOApr 16, 2003
Beta0.66
ATR, 14d0.14
Rel volume0.85
Short float0.92%
Insider own33.96%
Inst own10.79%

Snapshot

6 groups

Valuation

Index-
Market Cap15.13M
Enterprise Value47.81M
Income-23.82M
Sales1.02M
Book/sh-2.13
Cash/sh0.62
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees92
IPOApr 16, 2003

Ratios

P/E-
Forward P/E-
PEG-
P/S14.83
P/B-
P/C1.93
P/FCF-
EV/EBITDA-
EV/Sales46.87
Quick Ratio0.27
Current Ratio0.27
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.45
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y26.60% 29.65%
Sales past 3/5Y52.41% -
EPS Y/Y TTM30.12%
Sales Y/Y TTM-23.95%
EPS Q/Q43.56%
Sales Q/Q-15.83%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own33.96%
Insider Trans24.16%
Inst Own10.79%
Inst Trans-0.02%
ROA-74.95%
ROE-
ROIC-
Gross Margin-5.71%
Oper. Margin-2454.53%
Profit Margin-2344.59%
SMA207.74%
SMA508.35%
SMA200-47.88%
Trades-

Technical

Shs Outstand10.82M
Shs Float8.33M
Short Float0.92%
Short Ratio2.14
Short Interest0.08M
52W High4.86 -75.33%
52W Low0.85 41.18%
Volatility11.87% 12.70%
ATR (14)0.14
RSI (14)54.49
Beta0.66
Rel Volume0.85
Avg Volume35.82K
Volume30,573

Performance

Perf Week-2.44%
Perf Month27.66%
Perf Quarter-27.77%
Perf Half Y-65.81%
Perf YTD-59.87%
Perf Year-71.01%
Perf 3Y-75.24%
Perf 5Y-94.85%
Perf 10Y-99.03%
Recom1.00
Target Price12.00
Prev Close1.12
Price1.20
Change %7.14%

Peers

Mkt cap
TickerCompanyMkt cap
LGVNLongeveron Inc10.52M
MESOMesoblast Ltd ADR1.78B
CELZCreative Medical Technology Holdings Inc4.79M
CELUCelularity Inc24.37M
CLGNCollPlant Biotechnologies Ltd7.48M
FBLGFibroBiologics Inc6.63M
LCTXLineage Cell Therapeutics Inc280.72M
BRTXBioRestorative Therapies Inc2.15M
BSEMBioStem Technologies Inc27.45M
VCELVericel Corp3.03B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Manieu Alexandre WeinsteinDirectorAug 25 '26Option Exercise0.0064107,566Oct 27 06:06 AM
Manieu Alexandre WeinsteinDirectorOct 23 '26Buy1.50833,3341,250,0012,083,334Oct 27 06:06 AM

News

latest 14 of 182
  • Pluri Adds ISO 9001 and ISO 13485 Certifications to Support PluriCDMO Commercial Expansion (GlobeNewswire)
  • Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments (GlobeNewswire) +6.25%
  • Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform (FinanceWire) +13.13%
  • Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine (GlobeNewswire)
  • Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company (GlobeNewswire) +16.67%
  • Ever After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat Productivity (GlobeNewswire)
  • Pluri: Fiscal Q4 Earnings Snapshot (Associated Press) -5.60%
  • Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor (GlobeNewswire)
  • Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment (GlobeNewswire)
  • Ever After Foods Acquires Fishway to Expand Integrated Food Production Technology Platform (GlobeNewswire)
  • Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK (GlobeNewswire)
  • Pluri Chairman Alejandro Weinstein's Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30% (GlobeNewswire)
  • Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing (GlobeNewswire)
  • Pluri: Fiscal Q3 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q32025-05-08-0.880--0.9370.43--
2024Q22024-02-05-1.920--0.9450.20--
2022Q32022-11-10-2.720-2.880-2.4460.230.001
2022Q22022-09-21-2.720-3.040-2.7230.000.001
2022Q12022-02-17-2.880--2.8580.00-1
2021Q42021-09-13-3.680-3.226-3.6470.000.001
2021Q32021-08-02-3.840-2.680-3.8500.000.00-
2021Q22021-05-06-3.920-2.120-3.9140.000.00-
2020Q32020-05-11-3.360-2.880-3.3700.000.003
2020Q22020-02-06-3.200-4.200-3.1990.020.003
2020Q12019-11-07-3.680-5.280-3.7070.000.002
2019Q42019-09-12-5.040-5.066-4.1160.000.002
2019Q32019-05-06-7.200-6.000-6.8780.000.66-
2019Q22019-02-06-5.600-6.800-5.9990.050.00-
2019Q12018-11-07-6.400-7.200-6.1840.000.00-
2018Q42018-09-12-6.400--6.3260.00--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2010FY-34.800-43.200-0.000.00
2012FY-25.866-25.800-23.2000.600.72
2013FY-30.240-28.400-29.6000.680.72
2014FY-33.600-46.400-33.6000.380.33
2015FY-30.666-27.734-0.390.39
2016FY-23.200-24.000-23.2002.852.85
2017FY-25.600-26.840-25.6000.000.00
2018FY-20.000-19.116-20.0000.050.05
2019FY-13.160-24.400-22.9020.050.05
2020FY-12.220-12.000-12.8160.010.00
2021FY-10.640-6.880-14.1900.00-
2022FY-10.240--0.23-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025Q4S2025-09-061000.400.400.40
2025Q4S2025-09-051000.400.400.40
2025Q4S2025-09-041000.400.400.40
2025Q4S2025-09-031000.400.400.40
2025Q4S2025-09-021000.400.400.40
2025Q4S2025-09-011000.400.400.40
2025Q4S2025-08-311000.400.400.40
2025Q4S2025-08-301000.400.400.40
2025Q4S2025-08-291000.400.400.40
2025Q4S2025-08-281000.400.400.40
2025Q4S2025-08-271000.400.400.40
2025Q4S2025-08-261000.400.400.40
2025Q4S2025-08-251000.400.400.40
2025Q4S2025-08-241000.400.400.40

Estimate history

EPS, annual-20-22.902-12.816-14.19-10.249-6.182-3.986-3.564-2.445
Period201820192020202120222023202420252026
EPS, quarterly-1.059-1.077-0.532-0.937-0.963-0.65-0.707-0.552-0.543
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Sales, annual0.050.0540.02300.2340.2870.3261.3361.016
Period201820192020202120222023202420252026
Sales, quarterly0.0960.3260.1850.4270.3980.3160.1980.1670.335
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Shares, annual1.421.8853.1873.9954.0635.1565.4087.89410.824
Period201820192020202120222023202420252026
Shares, quarterly5.4085.5075.5657.7757.8948.1639.97810.43110.824
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue1.021.021.340.330.290.230.000.020.05
Cost of Goods Sold Incl. D&A1.071.071.000.260.371.051.371.571.96
Gross Profit-0.06-0.060.340.07-0.08-0.82-1.37-1.55-1.91
Selling, General and Administrative Excl. Other24.8824.8822.5122.2327.1640.7749.2527.9333.62
Research and Development15.0915.0912.8512.4515.7423.4128.8120.1224.59
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-24.94-24.94-22.18-22.16-27.25-41.59-50.62-29.48-35.53
Interest Expense0.930.930.870.870.840.890.080.200.00
Unusual Expense-0.27-0.27-0.81-0.150.160.37-0.04-0.010.10
Net Income Before Taxes-25.39-25.39-23.25-21.34-28.89-41.37-49.87-29.15-35.31
Income Taxes-0.03-0.03-0.010.000.000.000.000.000.00
Consolidated Net Income-25.37-25.37-23.25-21.34-28.89-41.37-49.87-29.15-35.31
Net Income From Continuing Operations-23.82-23.82-22.58-20.89-28.32-41.24-49.87-29.15-35.31
Net Income-23.82-23.82-22.58-20.89-28.32-41.24-49.87-29.15-35.31
EPS (Recurring)-2.22-2.46-3.65-4.01-6.16-10.18-14.20-12.82-22.85
EPS (Basic, Before Extraordinaries)-2.45-2.44-3.56-3.99-6.18-10.25-14.19-12.82-22.90
EPS (Diluted)-2.45-2.44-3.56-3.99-6.18-10.25-14.19-12.82-22.90
EBITDA-24.43-24.43-21.86-21.91-26.88-40.54-49.25-27.91-33.57
Non-Operating Income (Expense)0.210.21-1.011.53-0.641.480.800.510.33
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.611.611.561.742.428.9113.972.564.40
Price To Sales Ratio22.2720.0423.4892.91102.42169.21-6,994.091,417.60
Gross Margin-5.71-5.7125.3021.17-29.27-350.00--6,726.09-3,537.04
Operating Margin-2,454.53-2,454.53-1,659.88-6,796.93-9,493.38-17,774.79--128,156.52-65,800.00
Net Margin-2,344.59-2,344.59-1,690.34-6,407.36-9,867.94-17,624.79--126,747.83-65,383.33
Shares Outstanding10.8210.827.895.415.164.063.993.191.89
Market Capitalization14.1214.1238.7731.15263.83318.301,005.531,761.427,435.24

Income statement, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q32025Q22025Q1
Total Revenue0.340.170.200.320.400.430.180.33
Cost of Goods Sold Incl. D&A0.260.240.240.330.300.360.140.19
Gross Profit0.07-0.07-0.04-0.010.100.060.040.14
Selling, General and Administrative Excl. Other5.626.466.466.336.725.465.005.33
Research and Development3.373.963.833.933.993.042.922.89
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.55-6.54-6.51-6.35-6.62-5.40-4.96-5.20
Interest Expense0.230.240.230.230.230.210.210.22
Unusual Expense0.08-0.01-0.05-0.29-0.740.04-0.050.00
Net Income Before Taxes-6.19-6.18-6.88-6.14-7.77-6.33-3.11-6.04
Income Taxes-0.00-0.01-0.01-0.01-0.010.000.000.00
Consolidated Net Income-6.19-6.17-6.87-6.13-7.77-6.33-3.11-6.04
Net Income From Continuing Operations-5.88-5.55-6.54-5.85-7.60-6.15-2.96-5.88
Net Income-5.88-5.55-6.54-5.85-7.60-6.15-2.96-5.88
EPS (Recurring)-0.54-0.55-0.71-0.67-1.03-0.93-0.54-1.08
EPS (Basic, Before Extraordinaries)-0.54-0.55-0.71-0.65-0.96-0.94-0.53-1.08
EPS (Diluted)-0.54-0.55-0.71-0.65-0.96-0.94-0.53-1.08
EBITDA-5.42-6.41-6.38-6.22-6.51-5.33-4.89-5.13
Non-Operating Income (Expense)-0.330.59-0.200.15-1.66-0.692.00-0.62
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.200.310.600.490.640.460.210.50
Price To Sales Ratio22.2731.6420.6830.3929.2527.3035.0155.23
Gross Margin21.49-43.11-21.72-4.7524.1214.9923.2441.41
Operating Margin-1,655.52-3,913.77-3,285.86-2,009.49-1,663.57-1,264.64-2,679.46-1,594.48
Net Margin-1,755.22-3,322.16-3,304.55-1,851.27-1,909.05-1,439.58-1,597.84-1,804.29
Shares Outstanding10.8210.439.988.167.897.785.575.51
Market Capitalization14.1234.1227.6736.5338.7730.1423.7633.09

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments7.8321.0430.2440.4456.0265.5546.3424.4030.59
Short Term Receivables0.220.720.650.531.321.491.611.420.85
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.680.340.220.440.400.330.510.550.60
Total Current Assets8.7322.0931.1141.4157.7567.3748.4626.3732.04
Net Property, Plant & Equipment7.738.727.258.329.012.233.773.845.68
Total Investments and Advances1.020.880.630.630.630.0012.650.400.38
Intangible Assets5.755.93-------
Other Assets1.651.060.540.440.6823.940.640.700.86
Total Assets24.8838.6839.5350.8068.0693.5465.5331.3138.96
Short Term Debt Incl. Current Port. of LT Debt28.4327.950.560.630.620.631.020.000.00
Accounts Payable0.700.870.961.811.782.531.972.283.26
Other Current Liabilities3.593.512.933.184.428.365.005.885.29
Total Current Liabilities32.7232.334.455.626.8311.527.998.168.55
Long Term Debt6.496.1029.0529.2828.1823.950.560.000.00
Provision for Risks Charges0.680.700.600.600.870.920.880.951.13
Deferred Tax Liabilities0.380.41-------
Other Liabilities2.040.000.000.000.000.000.000.380.78
Total Liabilities42.3139.5534.1135.5035.8836.399.439.4910.45
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-23.04-6.840.1013.3630.0457.1556.1021.8228.51
Total Shareholders Equity-23.04-6.840.1013.3630.0457.1556.1021.8228.51
Accumulated Minority Interest5.605.985.321.952.150.000.000.000.00
Total Equity-17.43-0.865.4215.3032.1957.1556.1021.8228.51
Total Liabilities & Stockholders Equity24.8838.6839.5350.8068.0693.5465.5331.3138.96
Book Value Per Share-2.13-0.870.022.597.3914.3117.6111.5720.08
Tangible Book Value Per Share-2.66-1.620.022.597.3914.3117.6111.5720.08
Full-Time Employees92127118134159162158165180
Price to Book Ratio-0.53-8.60-84.892.481.332.214.028.584.07
Return on Assets-74.95-57.75-46.25-47.65-51.04-62.70-60.21-100.49-68.31
Return on Equity---310.58-130.53-94.60-88.06-74.82-140.31-88.93
Return on Invested Capital---71.66-66.43-70.84-61.49-51.45-161.80-91.65
Quick Ratio0.270.686.987.378.465.856.073.233.75
Current Ratio0.270.686.987.378.465.856.073.233.75

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-25.37-25.37-23.25-21.34-28.89-41.37-49.87-29.15-35.31
Depreciation0.510.510.320.250.361.051.371.571.96
Other Funds (Non Cash)3.693.690.532.874.8112.1213.972.565.15
Funds from Operations-21.17-21.17-22.40-18.22-23.72-28.20-34.53-25.02-28.20
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.581.584.190.200.86-6.123.54-1.35-1.25
Cash from Operating Activities-19.59-19.59-18.21-18.02-22.86-34.33-30.99-26.37-29.45
Capital Expenditures-0.63-0.63-1.62-0.32-0.26-0.28-0.37-0.27-0.24
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.020.020.370.000.000.000.000.000.00
Purchase or Sale of Investments10.5210.529.2710.919.9612.06-6.89-30.191.41
Purchase of Investments0.000.000.000.000.000.00-10.95-30.19-0.01
Sale Or Maturity of Investments10.5210.529.2710.919.9612.064.060.001.42
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities9.909.908.0310.589.7011.78-7.26-30.461.17
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock6.326.329.538.848.020.0036.9560.8723.48
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock6.326.329.538.848.020.0036.9560.8723.48
Proceedsfrom Stock Options1.251.25-0.058.750.000.0036.5958.160.00
Issuance or Reduction of Debt, Net0.000.000.000.000.00-2.1724.530.000.00
Change in Long Term Debt0.000.000.000.000.000.0024.450.000.00
Issuance of Long Term Debt0.000.000.000.000.000.0024.450.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.710.710.000.000.007.500.000.000.11
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities7.047.049.538.848.025.3361.4860.8723.58
Exchange Rate Effect0.030.030.180.01-0.02-3.21-0.62--
Net Change in Cash-2.62-2.62-0.471.42-5.16-20.4322.614.04-4.70
Free Cash Flow-20.22-20.22-19.83-18.34-23.12-34.61-31.36-26.64-29.69
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Cash & Short Term Investments7.839.5512.7115.4821.0426.68
Short Term Receivables0.220.100.170.290.720.18
Inventories0.000.000.000.000.000.00
Other Current Assets0.680.820.931.140.340.60
Total Current Assets8.7310.4613.8016.9222.0927.45
Net Property, Plant & Equipment7.738.049.118.528.728.62
Total Investments and Advances1.020.950.940.910.880.79
Intangible Assets5.755.795.845.885.93-
Other Assets1.650.810.901.441.060.54
Total Assets24.8826.0630.6033.6738.6837.41
Short Term Debt Incl. Current Port. of LT Debt28.4328.0328.4928.2127.950.60
Accounts Payable0.700.741.010.880.870.93
Other Current Liabilities3.593.232.843.073.514.18
Total Current Liabilities32.7232.0132.3532.1632.335.71
Long Term Debt6.495.606.146.036.1030.59
Provision for Risks Charges0.680.630.620.720.700.63
Deferred Tax Liabilities0.380.390.400.410.41-
Other Liabilities2.040.430.300.000.000.00
Total Liabilities42.3139.0639.8139.3239.5536.92
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-23.04-18.60-14.61-11.36-6.84-4.47
Total Shareholders Equity-23.04-18.60-14.61-11.36-6.84-4.47
Accumulated Minority Interest5.605.605.395.715.984.96
Total Equity-17.43-13.00-9.21-5.65-0.860.48
Total Liabilities & Stockholders Equity24.8826.0630.6033.6738.6837.41
Book Value Per Share-2.13-1.78-1.46-1.39-0.87-0.58
Tangible Book Value Per Share-2.66-2.34-2.05-2.11-1.62-0.58
Full-Time Employees92---127-
Price to Book Ratio-0.53-2.32-2.15-5.17-8.60-2.98
Return on Assets-74.95-80.48-85.06-65.26-57.75-56.14
Return on Invested Capital------23.54
Quick Ratio0.270.330.430.530.684.81
Current Ratio0.270.330.430.530.684.81

Cash flow, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Net Income-6.19-6.17-6.87-6.13-7.77-6.33
Depreciation0.120.130.130.130.110.07
Other Funds (Non Cash)0.471.130.741.35-0.380.54
Funds from Operations-5.60-4.91-6.00-4.65-8.04-5.72
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.160.400.80-0.782.831.42
Cash from Operating Activities-4.44-4.51-5.21-5.43-5.22-4.30
Capital Expenditures-0.03-0.04-0.45-0.12-0.72-0.58
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.020.000.000.000.370.00
Purchase or Sale of Investments1.621.833.103.973.38-3.65
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments1.621.833.103.973.38-3.65
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities1.611.792.663.853.03-4.23
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.531.252.540.00-0.439.97
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.531.252.540.00-0.439.97
Proceedsfrom Stock Options1.250.000.000.00-0.050.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.280.130.300.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.821.382.840.00-0.439.97
Exchange Rate Effect0.000.09-0.04-0.020.13-0.03
Net Change in Cash-0.02-1.260.26-1.60-2.501.40
Free Cash Flow-4.47-4.56-5.65-5.54-5.94-4.88

Revenue breakdown

Biological Products, (No Diagnostic Substances)2025: 1.34M 2026: 1.02M
Israel2025: 1.34M 2026: 1.02M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.92%0.1M8.3M34.33K
2026-10-150.25%0.0M8.3M22.43K
2026-09-300.25%0.0M7.7M31.45K
2026-09-150.26%0.0M7.6M29.96K
2026-08-310.42%0.0M6.3M29.33K
2026-08-140.25%0.0M6.2M26.08K
2026-07-310.30%0.0M6.2M25.29K
2026-07-150.39%0.0M6.2M21.74K
2026-06-300.25%0.0M6.2M10.82K
2026-06-150.27%0.0M6.2M10.25K
2026-05-290.31%0.0M5.9M8.96K
2026-05-150.30%0.0M5.9M6.93K
2026-04-300.35%0.0M5.9M7.76K
2026-04-150.37%0.0M6.5M8.37K
2026-03-310.41%0.0M6.2M9.31K
2026-03-130.42%0.0M6.2M15.94K
2026-02-270.46%0.0M6.2M24.71K
2026-02-130.47%0.0M6.2M28.95K
2026-01-300.39%0.0M5.7M38.30K
2026-01-150.32%0.0M5.7M37.31K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-308-KCurrent report2026-10-21SEC
2026-10-27SCHEDULE 13D/ASEC
2026-10-274Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-10-208-KCurrent report2026-10-19SEC
2026-10-15EFFECTEffectiveness filing by commission orderSEC
2026-10-06S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-09-11S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-1010-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-04DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-28424B5SEC
2026-08-288-KCurrent report2026-08-26SEC
2026-08-27424B3SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-178-KCurrent report2026-08-12SEC
2026-07-148-KCurrent report2026-07-14SEC
2026-07-138-KCurrent report2026-07-07SEC
2026-07-073Initial statement of beneficial ownership of securities2026-06-19SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-01SCHEDULE 13D/ASEC
2026-06-228-KCurrent report2026-06-15SEC
2026-06-018-KCurrent report2026-05-28SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-05-01SCHEDULE 13D/ASEC
2026-04-23ARSAnnual report to security holders. 2025-06-30SEC
2026-04-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-101.25M100
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
RENAISSANCE TECHNOLOGIES LLC0.17%
MORGAN STANLEY0.03%
EverSource Wealth Advisors, LLC0.02%
UBS Group AG0.00%
BARCLAYS PLC0.00%
SIMA Wealth Partners, LLC0.00%
CITIGROUP INC0.00%
WELLS FARGO & COMPANY/MN0.00%
JPMORGAN CHASE & CO0.00%
ROYAL BANK OF CANADA0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.02%
Dimensional International Small Cap ETF0.00%

OakChart. PLUR. Cached 15 minutes.

Some panels did not load: ratings.